<DOC>
	<DOCNO>NCT02175966</DOCNO>
	<brief_summary>The purpose study determine whether combination Daclatasvir ( DCV ) , Asunaprevir ( ASV ) , BMS-791325 Sofosbuvir effective safe treat Hepatitis-C virus .</brief_summary>
	<brief_title>Short Duration Combination Therapy With Daclatasvir , Asunaprevir , BMS-791325 Sofosbuvir Subjects Infected With Chronic Hepatitis-C ( FOURward Study )</brief_title>
	<detailed_description>Allocation : Initial Therapy : Randomized Controlled Trial : Participants assign intervention group chance Rescue Therapy : Nonrandomized Trial : Participants expressly assign intervention group non-random method physician choice Number Arms : Initial Therapy : 2 Groups Rescue Therapy : 2 Groups</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Males Females ≥18 year age , inclusive Chronic HCV infection Genotype 1 Noncirrhotic Treatment naive subject previous exposure Interferon formulation ( ie , IFNα , pegIFNα ) , ribavirin ( RBV ) HCV Direct Acting Antiviral ( DAA ) ( protease , polymerase inhibitor , etc . ) HCV Genotype Genotype 1 Documented suspect hepatocellular carcinoma Evidence decompensated liver disease Contraindication ( ) Peg/RBV therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>